BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gazouli I, Kyriazoglou A, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, Chatzidakis I, Kavourakis G, Economopoulou P, Kontogeorgakos V, Papagelopoulos P, Psyrri A. Systematic Review of Recurrent Osteosarcoma Systemic Therapy. Cancers (Basel) 2021;13:1757. [PMID: 33917001 DOI: 10.3390/cancers13081757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Peng L, Fang H, Yang X, Zeng X. Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. Front Chem 2022;10:847621. [DOI: 10.3389/fchem.2022.847621] [Reference Citation Analysis]
2 Liang L, Li G, Ye X. The Roles of KIFC1 in the Development of Osteosarcoma: Characterization of Potential Therapeutic Targets. Computational and Mathematical Methods in Medicine 2022;2022:1-10. [DOI: 10.1155/2022/5039134] [Reference Citation Analysis]
3 Mohás A, Krencz I, Váradi Z, Arató G, Felkai L, Kiss DJ, Moldvai D, Sebestyén A, Csóka M. In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma. Pathol Oncol Res 2022;28:1610231. [PMID: 35392503 DOI: 10.3389/pore.2022.1610231] [Reference Citation Analysis]
4 Sun X, Shan HJ, Yin G, Zhang XY, Huang YM, Li HJ. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V. Cell Death Discov 2022;8:48. [PMID: 35115496 DOI: 10.1038/s41420-022-00838-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D. Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers. Cancers (Basel) 2022;14:360. [PMID: 35053522 DOI: 10.3390/cancers14020360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang Y, He R, Lei X, Mao L, Jiang P, Ni C, Yin Z, Zhong X, Chen C, Zheng Q, Li D. A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma. Front Genet 2021;12:780780. [PMID: 34899864 DOI: 10.3389/fgene.2021.780780] [Reference Citation Analysis]
7 Suri M, Soni N, Okpaleke N, Yadav S, Shah S, Iqbal Z, Alharbi MG, Kalra HS, Hamid P. A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review. Cureus 2021;13:e18349. [PMID: 34725602 DOI: 10.7759/cureus.18349] [Reference Citation Analysis]
8 Wei X, Tang Z, Wu H, Zuo X, Dong H, Tan L, Wang W, Liu Y, Wu Z, Shi L, Wang N, Li X, Xiao X, Guo Z. Biofunctional magnesium-coated Ti6Al4V scaffolds promote autophagy-dependent apoptosis in osteosarcoma by activating the AMPK/mTOR/ULK1 signaling pathway. Mater Today Bio 2021;12:100147. [PMID: 34704011 DOI: 10.1016/j.mtbio.2021.100147] [Reference Citation Analysis]
9 Li S. The basic characteristics of extracellular vesicles and their potential application in bone sarcomas. J Nanobiotechnology 2021;19:277. [PMID: 34535153 DOI: 10.1186/s12951-021-01028-7] [Reference Citation Analysis]
10 Serra M, Hattinger CM, Pasello M, Casotti C, Fantoni L, Riganti C, Manara MC. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not? Cells 2021;10:2461. [PMID: 34572110 DOI: 10.3390/cells10092461] [Reference Citation Analysis]
11 Higuchi T, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, Bouvet M, Tsuchiya H, Hoffman RM. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib. Cancer Genomics Proteomics 2021;18:637-43. [PMID: 34479916 DOI: 10.21873/cgp.20286] [Reference Citation Analysis]
12 Moonmuang S, Chaiyawat P, Jantrapirom S, Pruksakorn D, Lo Piccolo L. Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma. Cancers 2021;13:4214. [DOI: 10.3390/cancers13164214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hecker-Nolting S, Maia Ferreira A, Bielack SS. Bone sarcoma: success through interdisciplinary collaboration. J Child Orthop 2021;15:331-6. [PMID: 34476022 DOI: 10.1302/1863-2548.15.210122] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ferreira de Oliveira JMP, Almeida JFD, Martins M, Proença C, Oliveira H, Fernandes E, Santos C. 3',4'-Dihydroxyflavonol Modulates the Cell Cycle in Cancer Cells: Implication as a Potential Combination Drug in Osteosarcoma. Pharmaceuticals (Basel) 2021;14:640. [PMID: 34358066 DOI: 10.3390/ph14070640] [Reference Citation Analysis]